The United Kingdom and the United States have secured a significant trade agreement that will preserve zero duties on UK pharmaceutical products entering the US market.
The Terms of the Pact
As part of the deal, the UK has committed to boost expenditure on drugs through the National Health Service (NHS). This commitment guarantees that duties on these vital exports will stay at zero for a duration of three years.
This deal follows previous statements to hike duties on patented drug imports, with potential rates mentioned as high as double the cost.
"This deal between the UK strengthens the worldwide climate for new treatments and establishes long-overdue equity to transatlantic pharmaceutical trade," a statement said.
Economic Impact
Drugs are one of the Britain's largest goods shipped to the America, which is easily the largest market for leading companies like GSK and AstraZeneca.
Statistics indicate that in the year prior to last September, the UK exported medicines worth £11.1bn to the US. This amount made up 17.4% of total UK exports in that span.
"This agreement protects work, increases funding and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Specific NHS Changes
The agreement includes several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to double overall NHS spending on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to control costs will be capped at 15%. In the past, repayments exceeded 20%.
Industry Background
This agreement follows a ongoing tension between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
The disagreement were exacerbated by assertions that American patients were paying significantly more for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or cancelled, while substantial expansions have been directed toward American operations.
A senior figure publicly accepted that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had declined as a share of its overall budget over the previous ten-year period.
